Investor Presentation for the Quarter and Half Year ended 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral Ltd reported weak Q2 FY26 results with revenue falling 14.5% YoY to INR 155.0 mn, EBITDA down 25.7% to INR 24.1 mn, and profit after tax (PAT) declining 28.6% to INR 16.4 mn. EBITDA margin contracted by 233 basis points YoY to 15.5% and PAT margin fell to 10.5%. For H1 FY26, revenue dropped 3.4% to INR 333.9 mn while PAT declined 16% to INR 33.7 mn. The injectables segment share grew to 60% of revenue in Q2 FY26 from 50% a year ago, while the tablets share shrank to 32.2% from 42.6%. Exports contributed 18.4% of Q2 revenue but rose to 77.4% for H1 FY26. The company highlights CDMO clients, a JV plant in Prague (Alevia Healthcare), and expansion plans covering new products, geographies, therapeutic areas, and partnerships.
The sharp declines in revenue, margins, and earnings across both Q2 and H1 FY26 signal operational weakness and could weigh negatively on short-term investor sentiment. However, the growing injectables mix, expanded exports, and new facility in Prague may support a gradual recovery if executed well.